A5048977427- Nausea and vomiting management
- Anesthesia and Pain Management
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Breast Cancer Treatment Studies
- Pathogenesis and Treatment of Hiccups
- Colorectal Cancer Treatments and Studies
- Sympathectomy and Hyperhidrosis Treatments
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Growth Hormone and Insulin-like Growth Factors
- Chemotherapy-induced organ toxicity mitigation
- Intraoperative Neuromonitoring and Anesthetic Effects
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Metabolism, Diabetes, and Cancer
- Advanced Breast Cancer Therapies
- Erythropoietin and Anemia Treatment
- Bone health and treatments
- Cancer Genomics and Diagnostics
- Blood Coagulation and Thrombosis Mechanisms
Fondazione IRCCS Istituto Nazionale dei Tumori
2013-2024
Casa di Cura Villa Garda
2021-2023
Azienda Socio Sanitaria Territoriale del Garda
2021-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2009-2023
Cancer Institute (WIA)
2017-2019
University of Milan
2012-2018
The Netherlands Cancer Institute
2000
Peter MacCallum Cancer Centre
2000
University of Naples Federico II
1991-1992
The 2015 MASCC–ESMO guideline for the prevention of ChT- and RINV was updated based on a literature search from 1 June through 31 January 2023. Thirty-four multidisciplinary experts reviewed literature. most important updates were as follows:1)Recommendation to use olanzapine part prophylaxis patients receiving HEC;2)Recommendation 1-day DEX schedule in treated with AC, carboplatin or other MEC;3)Suggestion include an NK1-RA antiemetic regimen women aged ≤50 years oxaliplatin;4)Suggestion...
PURPOSE: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment nonsteroidal inhibitor. PATIENTS AND METHODS: In this phase II trial, eligible patients were treated exemestane 25 mg daily (n = 241) followed, at time PD was determined, by 100 58). RESULTS: On basis intent-to-treat analysis independent review, produced objective responses 6.6%...
Chromogranin A (CgA), neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and urinary 5-hydroxyindole-3-acetic acid (5-HIAA) are the markers currently used in diagnosis, prognosis, follow-up of patients with neuroendocrine tumors (NETs). The authors examined role such biomarkers a large series NETs.One hundred twenty-seven entered study. Multiple blood 24-hour urine specimens were assayed for biomarker quantitation.The accuracy each marker was assessed (n = 106) without 21)...
Purpose To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer. Patients Methods Seventy-three eligible patients (median age, 73 years; range, 65 to 89 years) were enrolled. The first 30 received oral 1,250 mg/m 2 twice daily on days 1 14 every 21 days. Due occurrence two toxic deaths, 1,000 was given subsequent 43 patients. Results All assessable for efficacy. A total 351 treatment cycles administered (median, six per patient; one eight cycles). Dose...
PURPOSE The aim of the study was to evaluate activity vinorelbine (VNLB) in a population advanced ovarian cancer patients, with particular attention defining its role platinum-resistant disease. PATIENTS AND METHODS Thirty-three patients were recruited and treated VNLB 25 mg/m2 intravenously (IV) weekly. median age 53 years, performance status 0 2, number previous chemotherapy regimens two (range, one five). Twenty-four platinum-resistant; remaining nine either platinum-sensitive (four...
Background. Using a wide range of interferon (IFN) doses and schedules, number authors have found them to be active against neuroendocrine tumors. Methods. To verify the clinical activity IFN, 49 evaluable patients with advanced stage low- intermediate-grade tumors were treated recombinant IFN-alpha-2a at daily dose 6 × 106 IU intramuscularly for 8 weeks, 3 times weekly thereafter. The predominant histotype was carcinoid, although few cases had malignant islet cell tumors, medullary thyroid...
A phase III trial assessed the efficacy of palonosetron plus dexamethasone given once in preventing acute and delayed chemotherapy-induced nausea vomiting (CINV) following a broad range moderately emetogenic chemotherapy (MEC) regimens.This multicentre, randomized, open-label, non-inferiority evaluated two different treatment groups. One group received (0.25 mg intravenously) (8 before chemotherapy, while other was administered same regimen on day 1 followed by 8 orally days 2 3. The primary...
Abstract Purpose This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide doses of > 1500 mg/m 2 combination an anthracycline (AC) women with breast cancer. Methods A report following PRISMA guidelines literature from January 1, 2015, until February 2023, was performed. PubMed (Ovid), Scopus (Google), Cochrane...
Abstract Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care Cancer/European Society for Medical Oncology (MASCC/ESMO) guidelines recommend with a neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine-3 (5-HT3RA), dexamethasone receiving highly emetogenic chemotherapy (HEC), including anthracycline-cyclophosphamide (AC)- carboplatin (considered moderately...
In cancer patients, hypercoagulability is a common finding. It has been associated with an increased risk of venous thromboembolism, but also to tumor proliferation and progression. this prospective study large cohort breast we aimed evaluate whether pre-chemotherapy abnormalities in hemostatic biomarkers levels: (i) are cancer-specific clinico-pathological features; (ii) can predict for disease recurrence. D-dimer, fibrinogen, prothrombin fragment 1+2, FVIIa/antithrombin levels were...
To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated noninferiority of DEX on day 1, with or without low-dose days 2 and 3, combined an oral fixed-dose combination netupitant palonosetron (NEPA), compared guideline-consistent use 4-day DEX.In this open-label, multicenter study, chemotherapy-naïve undergoing high-dose cisplatin (≥70 mg/m2 ), were given NEPA (12 mg) 1 randomized (1:1:1 ratio) receive either (a) no further...